Objective—To determine effectiveness of infusion of
1 and 2% enilconazole for treatment of nasal and
sinusal aspergillosis, respectively, in dogs.
Animals—26 client-owned dogs with aspergillosis.
Procedure—All dogs had typical clinical signs of
aspergillosis and rhinoscopically visible intrasinusal or
intranasal fungal plaques associated with turbinate
destruction. During rhinoscopy, affected nasal cavities
and frontal sinuses were debrided meticulously.
Nineteen dogs (group A) were treated with 1% enilconazole
by use of a modified noninvasive infusion
procedure. Seven dogs (group B) were treated with
2% enilconazole via catheters that were placed via
endoscopic guidance into the frontal sinuses. All dogs
underwent follow-up rhinoscopy for determination of
further treatment until cure was established.
Results—Age, disease duration, clinical score, and
rhinoscopic score were similar for both groups before
treatment. In group A, 17 of 19 dogs were cured; 9,
6, and 2 dogs were cured after 1, 2, or 3 treatments,
respectively. The remaining 2 dogs were euthanatized
before the end of the treatment protocol. In
group B, all dogs were cured; 6 dogs and 1 dog were
cured after 1 or 2 treatments, respectively. Only
minor adverse effects such as nasal discharge, epistaxis,
and sneezing developed.
Conclusions and Clinical Relevance—After extensive
rhinoscopic debridement, 1 and 2% enilconazole
infused into the nasal cavities and the frontal sinuses,
respectively, were effective for treatment of
aspergillosis in dogs. Intrasinusal administration via
endoscopically placed catheters appeared to require
fewer infusions for success. Follow-up rhinoscopy is
strongly advised. (J Am Med Vet Assoc 2002;221:1421–1425)